Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Survivorship
Published in: Journal of Cancer Survivorship 3/2013

01-09-2013

The EKZ/AMC childhood cancer survivor cohort: methodology, clinical characteristics, and data availability

Authors: E. Sieswerda, R. L. Mulder, I. W. E. M. van Dijk, E. C. van Dalen, S. L. Knijnenburg, H. J. H. van der Pal, M. S. Mud, R. C. Heinen, H. N. Caron, L. C. M. Kremer

Published in: Journal of Cancer Survivorship | Issue 3/2013

Login to get access

Abstract

Purpose

Childhood cancer survivors are at high risk of late adverse effects of cancer treatment, but there are still many gaps in evidence about these late effects. We described the methodology, clinical characteristics, data availability, and outcomes of our cohort study of childhood cancer survivors.

Methods

The Emma Children’s Hospital/Academic Medical Center (EKZ/AMC) childhood cancer survivor cohort is an ongoing single-center cohort study of ≥5-year childhood cancer survivors, which started in 1996 simultaneously with regular structured medical outcome assessments at our outpatient clinic.

Results

From 1966 to 2003, 3,183 eligible children received primary cancer treatment in the EKZ/AMC, of which 1,822 (57.2 %) survived ≥5 years since diagnosis. Follow-up time ranged from 5.0 to 42.5 years (median, 17.7). Baseline primary cancer treatment characteristics were complete for 1,781 (97.7 %) survivors, and 1,452 (79.7 %) survivors visited our outpatient clinic. Baseline characteristics of survivors who visited the clinic did not differ from those without follow-up. Within our cohort, 54 studies have been conducted studying a wide range of late treatment-related effects.

Conclusions

The EKZ/AMC childhood cancer survivor cohort provides a strong structure for ongoing research on the late effects of childhood cancer treatment and will continuously contribute in reducing evidence gaps concerning risks and risk groups within this vulnerable population.

Implications for Cancer Survivors

Our large cohort study of childhood cancer survivors with complete baseline characteristics and unique, long-term medical follow-up decreases gaps in evidence about specific risks of late effects and high-risk groups, with the ultimate goal of improving the quality of care for childhood cancer survivors.
Appendix
Available only for authorised users
Literature
1.
Curry HL, Parkes SE, Powell JE, et al. Caring for survivors of childhood cancers: the size of the problem. Eur J Cancer. 2006;42:501–8.PubMedCrossRef
2.
Gatta G, Zigon G, Capocaccia R, et al. Survival of European children and young adults with cancer diagnosed 1995–2002. Eur J Cancer. 2009;45:992–1005.PubMedCrossRef
3.
Geenen MM, Cardous-Ubbink MC, Kremer LC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297:2705–15.PubMedCrossRef
4.
Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008;100:1368–79.PubMedCrossRef
5.
Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572–82.PubMedCrossRef
6.
Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010;304:172–9.PubMedCrossRef
7.
Reulen RC, Frobisher C, Winter DL, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA. 2011;305:2311–9.PubMedCrossRef
8.
Oeffinger KC, van Leeuwen FE, Hodgson DC. Methods to assess adverse health-related outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev. 2011;20:2022–34.PubMedCrossRef
9.
Jaspers MW, Caron H, Behrendt H, et al. The development of a new information model for a pediatric cancer registry on late treatment sequelae in The Netherlands. Stud Health Technol Inform. 2000;77:895–9.PubMed
10.
11.
Cardous-Ubbink MC, Heinen RC, Langeveld NE, et al. Long-term cause-specific mortality among five-year survivors of childhood cancer. Pediatr Blood Cancer. 2004;42:563–73.PubMedCrossRef
12.
Cardous-Ubbink MC, Heinen RC, Bakker PJ, et al. Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer. 2007;43:351–62.PubMedCrossRef
13.
Cardous-Ubbink MC, Geenen MM, Schade KJ, et al. Hypertension in long-term survivors of childhood cancer: a nested case–control study. Eur J Cancer. 2010;46:782–90.PubMedCrossRef
14.
van der Pal HJ, van Dalen EC, van Delden DE, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012;30:1429–37.PubMedCrossRef
15.
van Dijk IW, Oldenburger F, Cardous-Ubbink MC, et al. Evaluation of late adverse events in long-term Wilms’ tumor survivors. Int J Radiat Oncol Biol Phys. 2010;78:370–8.PubMedCrossRef
16.
van Dalen EC, van der Pal HJ, van den Bos C, et al. Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines. Eur J Cancer. 2006;42:2549–53.PubMedCrossRef
17.
Geenen MM, Bakker PJ, Kremer LC, et al. Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy. Pediatr Blood Cancer. 2010;55:690–7.PubMedCrossRef
18.
Heikens J, Michiels EM, Behrendt H, et al. Long-term neuro-endocrine sequelae after treatment for childhood medulloblastoma. Eur J Cancer. 1998;34:1592–7.PubMedCrossRef
19.
Heikens J, Ubbink MC, van der Pal HP, et al. Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease. Cancer. 2000;88:2116–21.PubMedCrossRef
20.
Knijnenburg SL, Jaspers MW, van der Pal HJ, et al. Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol. 2012;7:1416–27.PubMedCrossRef
21.
Mulder RL, Thonissen NM, van der Pal HJ, et al. Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer. Thorax. 2011;66:1065–71.PubMedCrossRef
22.
Noorda EM, Somers R, van Leeuwen FE, et al. Adult height and age at menarche in childhood cancer survivors. Eur J Cancer. 2001;37:605–12.PubMedCrossRef
23.
Tromp K, Claessens JJ, Knijnenburg SL, et al. Reproductive status in adult male long-term survivors of childhood cancer. Hum Reprod. 2011;26:1775–83.PubMedCrossRef
24.
van der Pal HJ, van Dalen EC, Hauptmann M, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 2010;170:1247–55.PubMedCrossRef
25.
van Santen HM, Vulsma T, Dijkgraaf MG, et al. No damaging effect of chemotherapy in addition to radiotherapy on the thyroid axis in young adult survivors of childhood cancer. J Clin Endocrinol Metab. 2003;88:3657–63.PubMedCrossRef
26.
Mulder RL, Kremer LC, Koot BG, et al. Surveillance of hepatic late adverse effects in a large cohort of long-term survivors of childhood cancer: prevalence and risk factors. Eur J Cancer. 2012;49:185–93.PubMedCrossRef
27.
Langeveld N, Ubbink M, Smets E. ‘I don’t have any energy’: the experience of fatigue in young adult survivors of childhood cancer. Eur J Oncol Nurs. 2000;4:20–8.PubMedCrossRef
28.
Langeveld NE, Grootenhuis MA, Voute PA, et al. No excess fatigue in young adult survivors of childhood cancer. Eur J Cancer. 2003;39:204–14.PubMedCrossRef
29.
Langeveld NE, Ubbink MC, Last BF, et al. Educational achievement, employment and living situation in long-term young adult survivors of childhood cancer in the Netherlands. Psychooncology. 2003;12:213–25.PubMedCrossRef
30.
Langeveld NE, Grootenhuis MA, Voute PA, et al. Posttraumatic stress symptoms in adult survivors of childhood cancer. Pediatr Blood Cancer. 2004;42:604–10.PubMedCrossRef
31.
Langeveld NE, Grootenhuis MA, Voute PA, et al. Quality of life, self-esteem and worries in young adult survivors of childhood cancer. Psychooncology. 2004;13:867–81.PubMedCrossRef
32.
Maurice-Stam H, Grootenhuis MA, Caron HN, et al. Course of life of survivors of childhood cancer is related to quality of life in young adulthood. J Psychosoc Oncol. 2007;25:43–58.PubMedCrossRef
33.
Maurice-Stam H, Oort FJ, Last BF, et al. A predictive model of health-related quality of life in young adult survivors of childhood cancer. Eur J Cancer Care (Engl). 2009;18:339–49.CrossRef
34.
Maurice-Stam H, Verhoof EJ, Caron HN, et al. Are survivors of childhood cancer with an unfavourable psychosocial developmental trajectory more likely to apply for disability benefits? Psychooncology. 2011;22:708–14.PubMed
35.
Stam H, Grootenhuis MA, Last BF. The course of life of survivors of childhood cancer. Psychooncology. 2005;14:227–38.PubMedCrossRef
36.
Stam H, Grootenhuis MA, Caron HN, et al. Quality of life and current coping in young adult survivors of childhood cancer: positive expectations about the further course of the disease were correlated with better quality of life. Psychooncology. 2006;15:31–43.PubMedCrossRef
37.
van Dijk M, Grootenhuis MA, de Boer M, et al. Alexithymia in long-term survivors of childhood cancer. Pediatr Rehabil. 2002;5:203–7.PubMed
38.
Aronson DC, Slaar A, Heinen RC, et al. Long-term outcome of bilateral Wilms tumors (BWT). Pediatr Blood Cancer. 2011;56:1110–3.PubMedCrossRef
39.
van Dijk IW, Cardous-Ubbink MC, van der Pal HJ, et al. Dose–effect relationships for adverse events after cranial radiation therapy in long-term childhood cancer survivors. Int J Radiat Oncol Biol Phys. 2013;85:768–75.PubMedCrossRef
40.
Hudson MM, Ness KK, Nolan VG, et al. Prospective medical assessment of adults surviving childhood cancer: study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort study. Pediatr Blood Cancer. 2011;56:825–36.PubMedCrossRef
41.
Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002;38:229–39.PubMedCrossRef
42.
Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol. 2009;27:2308–18.PubMedCrossRef
43.
Hawkins MM, Lancashire ER, Winter DL, et al. The British Childhood Cancer Survivor Study: objectives, methods, population structure, response rates and initial descriptive information. Pediatr Blood Cancer. 2008;50:1018–25.PubMedCrossRef
44.
McBride ML, Rogers PC, Sheps SB, et al. Childhood, adolescent, and young adult cancer survivors research program of British Columbia: objectives, study design, and cohort characteristics. Pediatr Blood Cancer. 2010;55:324–30.PubMedCrossRef
45.
Kuehni CE, Rueegg CS, Michel G, et al. Cohort profile: the Swiss Childhood Cancer Survivor Study. Int J Epidemiol. 2012;41:1553–64.PubMedCrossRef
46.
Stricker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol. 2010;25:245–51.PubMedCrossRef
47.
48.
Laupacis A, Wells G, Richardson WS, et al. Users’ guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA. 1994;272:234–7.PubMedCrossRef
49.
Visscher H, Ross CJ, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30:1422–8.PubMedCrossRef
50.
Bhatia S. Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev. 2011;20:2048–67.PubMedCrossRef
Metadata
Title
The EKZ/AMC childhood cancer survivor cohort: methodology, clinical characteristics, and data availability
Authors
E. Sieswerda
R. L. Mulder
I. W. E. M. van Dijk
E. C. van Dalen
S. L. Knijnenburg
H. J. H. van der Pal
M. S. Mud
R. C. Heinen
H. N. Caron
L. C. M. Kremer
Publication date
01-09-2013
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 3/2013
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-013-0283-9

Other articles of this Issue 3/2013

Journal of Cancer Survivorship 3/2013 Go to the issue

OriginalPaper

Potential gonadotoxicity of treatment in relation to quality of life and mental well-being of male survivors of childhood acute lymphoblastic leukemia

OriginalPaper

Are survivorship care plans responsive to African-American breast cancer survivors?: voices of survivors and advocates

OriginalPaper

Factors related to decision making and substance use in adolescent survivors of childhood cancer: a presenting clinical profile

OriginalPaper

Dose–response relationships between physical activity, social participation, and health-related quality of life in colorectal cancer survivors

Review

Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies

OriginalPaper

Objectively measured physical activity among US cancer survivors: considerations by weight status
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits